Bruce N. Jacobs

CFO Bruce N. Jacobs sells 77,109 shares for $8,864,828.98 at Kymera (KYMR); 10b5-1 plan execution.

Bruce N. Jacobs, CFO of Kymera Therapeutics, executed 8 separate sales totaling 77,109 shares for $8,864,828.98 on 2026-06-30, reducing his direct holdings from 321,992 shares to 244,883 shares (-23.9%). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The sales occurred at prices ranging from $110.54 to $117.70 per share (blended average $114.96), with the largest single transaction being 51,375 shares at $114.77. The company remains unprofitable (net income of -$69,234,000 on quarterly revenue of $34,365,000), and fundamental trends show annual revenue decline of -16.7% year-over-year. Notably, the CFO's prior five sales at KYMR (all on 2026-03-04 and 2026-03-02) were followed by consistently negative returns at both the 30-day and 90-day horizons, with 90-day outcomes ranging from -7.2% to -17.7%. The current stock price of $113.51 represents a -12.7% retreat from the 52-week high of $130.05, though the stock has rallied +59.2% over the prior 30 days.

CFO Jacobs sold 12,471 shares (12.5K shares) for $1,091,230.63 ($1.1M) across 7 transactions on 2026-03-02 to 2026-03-04.

Jacobs Bruce N., Chief Financial Officer at Kymr, executed 7 separate sales totaling 12,471 shares for $1,091,230.63 ($1.1M) across two trading days at prices ranging from $84.00 to $89.66, with a blended average of $87.50. This represents a 5.1% reduction in his holdings, leaving him with 232,588 shares post-transaction. The sales occurred as the stock traded near its 52-week high of $95.03 (current price $86.11 is 9.4% below that peak), and within a 30-day window of +13.9% appreciation. His prior sale at Kymr on 2025-09-17 saw the stock gain 68.4% in the 90-day period following, a pattern of poor timing that did not repeat here—though it is not yet possible to assess the full 90-day outcome of this March 2026 filing. The company remains unprofitable with a net income of $-82,175,000.00 against quarterly revenue of $2,764,000.00 and annual revenue decline of -16.7%, providing limited visibility into near-term cash generation.

CFO Bruce N. Jacobs sold 79,220 shares of KYMR at $50.00 on 2025-09-17 for $3,961,380.26; reduced holdings 25.8% despite -40.1% revenue decline

CFO Bruce N. Jacobs sold 79,220 shares at $50.00, reducing his post-transaction holdings to 227,409 shares (a 25.8% reduction from 306,629 shares). The sale occurred as Kymera continues to operate unprofitably with net income of $-76,614,000.00 and annual revenue declining -40.1%. The timing of this material reduction in CFO stake—worth $3,961,380.26—while the company faces significant revenue headwinds and ongoing losses merits investor scrutiny regarding management confidence in near-term execution.